期刊文献+

临床药师对1例疑似瑞舒伐他汀致肌酸激酶升高患者的病例分析 被引量:4

One Case of Rosuvastatin Induced Creatine Kinase Elevation Reported by Clinical pharmacist
暂未订购
导出
摘要 一例64岁女性患者,以反复心悸、头晕5个月,加重1个月入院,入院后第二天发现肌酸激酶异常升高,瑞舒伐他汀的应用可能会导致患者的肌酸激酶升高。临床药师从肌酸激酶升高的常见原因,患者的既往用药、药物的不良反应、以及患者的身体状况等多方面进行分析,并结合相关研究资料向临床提供合理建议。 One 64-year-old female patient with repeated palpitation and dizziness for five months was sent to hospital after her symptoms getting more serious for 1 month.On the second day,the patient was found with increased creatine kinase,which might be caused by the application of rosuvastatin.Clinical pharmacists analyzed the common reason of creatine kinase elevations,the usage of drugs,adverse drug reaction,and the physical condition of patient,and finally provided reasonable suggestions to clinical uses.
作者 邵兵 刘高峰
出处 《药品评价》 CAS 2013年第10期40-42,共3页 Drug Evaluation
关键词 瑞舒伐他汀 肌酸激酶升高 临床药师 Rosuvastatin Creatine Kinase Elevations Clinical Pharmacists
  • 相关文献

参考文献4

二级参考文献168

共引文献5275

同被引文献43

  • 1Giuseppe Famularo,Luca Miele,Giovanni Minisola,Antonio Grieco.Liver toxicity of rosuvastatin therapy[J].World Journal of Gastroenterology,2007,13(8):1286-1288. 被引量:9
  • 2Hanaa A. El Gendy,Noha M. Elsharnouby.Safety and vasopressor effect of rosuvastatin in septic patients[J].Egyptian Journal of Anaesthesia.2014
  • 3Kazuyoshi Kaneko,Hiroki Saito,Tetsuya Takahashi,Nobuyuki Kiribayashi,Koki Ohmi,Toshiki Sasaki,Takeshi Niizeki,Shigeo Sugawara,Masahiro Akasaka,Isao Kubota.Rosuvastatin Improves Plaque Morphology in Cerebral Embolism Patients with Normal Low-Density Lipoprotein and Severe Aortic Arch Plaque[J].Journal of Stroke and Cerebrovascular Diseases.2014
  • 4Rajkiran Mahalwar,Deepa Khanna.Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders[J].European Journal of Pharmacology (-).2013(1-3)
  • 5Evan A. Stein,Donald G. Vidt,James Shepherd,Valerie A. Cain,Deborah Anzalone,Michael D. Cressman.Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program[J].Atherosclerosis.2012(2)
  • 6Judith Hsia,Jean G. MacFadyen,John Monyak,Paul M. Ridker.Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin[J].Journal of the American College of Cardiology.2011(16)
  • 7James Shepherd,Donald B. Hunninghake,Evan A. Stein,John J.P. Kastelein,Susan Harris,John Pears,Howard G. Hutchinson.Safety of rosuvastatin[J].The American Journal of Cardiology.2004(7)
  • 8Akoglu H, Yilmaz R, Kirkpantur A, et al. Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure[J], Ann Pharmacother, 2007, 41(1): 143-147.
  • 9Gallelli L, Ferraro M, Spagnuolo V, et al. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation[J]. Drug Metabol Drug Interact, 2009, 24(1): 83-87.
  • 10汪翼.肌酸激酶升高的临床意义与特发性高肌酸激酶血症[J].中国实用儿科杂志,2009,24(6):494-496. 被引量:33

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部